4-butyrolactone has been researched along with Dermatitis, Atopic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, J; Sun, L; Wang, P; Xu, Q; Yu, L; Zhang, L; Zheng, Z; Zhou, J; Zuo, D | 1 |
1 other study(ies) available for 4-butyrolactone and Dermatitis, Atopic
| Article | Year |
|---|---|
Secoisolariciresinol diglucoside-derived metabolite, enterolactone, attenuates atopic dermatitis by suppressing Th2 immune response.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents; Butylene Glycols; Child, Preschool; Dermatitis, Atopic; Dinitrochlorobenzene; Glucosides; Humans; Immunity; Lignans; Mice; Mice, Inbred BALB C; Skin | 2022 |